Category Archives: crizotinib – Xalkori from Pfizer

Outcomes for ALK+ patients

Abstract e20550 is from Spain and involves 49 patients. Patients took 6 different ALK inhibitors. The abstract concluded “ALK+ patients who received targeted agents have prolonged survival despite brain metastases…. ALK inhibitors improve intracranial response rate and survival.”

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Discontinuing Crizotinib treatment

Abstract e20610 is from Canada and covers 97 patients. Post Crizotinib treatment 43% received Ceritinib, 20% received chemo and 37% received no additional treatment. Median overall survival was: 0.9 months for those who received no additional treatment, 7.6 months for … Continue reading

Posted in ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

HSP90 and Crizotinib

Abstract 9059 basically flung that administrating an HSP90 inhibitor at the same time as Crizotinib did not delay the development of resistance to Crizotinib.

Posted in crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

Crizotinib and children

Abstract 11509 covers 107 pediatric patients and their tumors. ALK alterations were found in 18 of them (not all are fusion mutations). The ages ranged from 3-16 years. 7 patients were still being treated at the data cut off. At … Continue reading

Posted in crizotinib - Xalkori from Pfizer, Glioblastomas, Neuroblastomas, Potential Treatments, Research, Side Effects | Leave a comment

Alectinib Japan trial abstract

Abstract 9008 covers the J-ALEX phase 3 trial comparing Crizotinib (arm A) with Alectinib (arm B) in TKI naive patients. There were 207 patients at 41 centers in Japan randomized between the two arms. Arm A had a median PFS … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, crizotinib - Xalkori from Pfizer, Lung cancer, Research, Resistance to treatment | Leave a comment

Upcoming ASCO abstracts

There are 14 abstracts for the upcoming ASCO that have ALK in the title. But only 6 look like they are likely to be broadly applicable to people on this board. I will be posting summaries over the next week … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer | Leave a comment

Long term phase 1 data for Ceritinib

On March 10 an article was published on the long term results of a phase 1 trial of Ceritinib. The trial enrolled 255 patients from January 2011 and July 2013 of whom 246 had ALK + lung cancer. Data cutoff … Continue reading

Posted in Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Research, Resistance to treatment, Side Effects | Leave a comment

Crizotinib approved for ROS1 + lung cancer

On March 11 the FDA approved the selling of Crizotinib for patients with ROS1 mutations in lung cancer. The ORR was 66% and the median DOR was 18.3 months. Safety profile was similar to that in ALK + patients. http://www.businesswire.com/news/home/20160311005839/en/XALKORI%C2%AE-crizotinib-Approved-U.S.-FDA-Treatment-Patients

Posted in crizotinib - Xalkori from Pfizer, Lung cancer, Regulatory applications & approvals | Leave a comment

Article by Dr. Shaw

Dr. Shaw discusses the recent approval of Alectinib and the treatment implications now that there are 3 ALK inhibitors approved by the FDA. http://www.ascopost.com/issues/january-25-2016/the-evolving-treatment-landscape-of-alk-positive-nsclc/

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Imunotherapies, Lung cancer, Potential Treatments, Research | Leave a comment

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Patients taking Pfizer’s Lorlatinib (after developing resistance to Crizotinib) can develop the L1198F mutation. The L1198F mutation causes the cancer cells that were previously resistant to Crizotinib to become sensitive to Crizotinib again. Essentially the two drugs can require mutually … Continue reading

Posted in 3922 - lorlatinib by Pfizer, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment